Analyst Conference Summaries

Biotechnology Investor Aids

Agenus
AGEN

conference date: October 29, 2020 @ 5:30 AM Pacific Time

Agenus: A Buy With iNKT Therapy, MK-4830 Milestone [November 13, 2020 at Seeking Alpha]

Agenus First Data From MK-4830: Another Reason To Buy September 23, 2020 @ Seeking Alpha

Agenus Approaches Stock-Propelling Events August 13, 2020 @ Seeking Alpha

Agenus 1181 Is A Potential Cancer Game Changer [May 27, 2020 at Seeking Alpha]

Agenus Reveals Improved Cancer Immunotherapy Therapy Results [March 16, 2020 at Seeking Alpha]

Older article links are below the conference tables

2020
Agenus
Q1 2020
Agenus
Q2 2020
Agenus
Q3 2020
 
May 7, 2020 Aug 6, 2020 Oct. 29, 2020  
2019
Agenus
Q1 2019
Agenus
Q2 2019
Agenus
Q3 2019
Agenus
Q4 2019
May 9, 2019 Aug. 8, 2019 Nov. 4, 2019 March 12, 2020
2018
Agenus
Q4 2018
May 7, 2018
Aug. 9, 2018
Nov. 6, 2018
Mar. 14, 2019
2017
May 4, 2017
August 3, 2017  
Nov. 7, 2017
March 15, 2018
2016
04/28/2016
07/28/2016
10/27/2016
03/09/2017 
2015
04/23/2015
07/23/2015
10/27/2015
03/03/2016
2014
05/08/2014
07/24/2014
10/31/2014
 02/26/2015
2013
not available
not available 
08/01/2013
10/24/2013
03/05/2014 

Agenus A Buy For Cancer Therapy Pipeline [February 26, 2020 at Seeking Alpha]

Agenus On A Roll With More Catalysts Ahead [November 19, 2019 at Seeking Alpha]

Agenus Is A Buy Long Term, Despite Short Interest [June 7, 2019 at Seeking Alpha]

Agenus Melts Down With Blockchain [February 26, 2019]

Agenus Illustrates Dilution And Non-Dilution Perils [June 26, 2018]

Agenus Mystery Therapy Indicates Possible Upside [March 19, 2018]

Incyte Buys Agenus Shares at $6, You Can Buy Them Cheaper [February 15, 2017]

Agenus QS-21 Stimulon part of GSK Malaria Vaccine Gets Positive Review in Europe [July 24, 2015 Agenus press release]

Why Agenus Can Continue to Rise After Doubling [May 15, 2015]

Agenus Platforms Provide Many Shots On Commercialization Goal May 13, 2014 at Seeking Alpha

Checkpoint Modulators and Combination Therapies for Cancer May 15, 2014 at The Chairman's Blog

Agenus Positive Phase II Glioblastoma (Brain Cancer) Results [July 1 Agenus press release]

Agenus (AGEN) is a development-stage biotechnology company specializing in immunology and cancer therapies including checkpoint modulators (CPMs).

Agenus web site
Agenus investor relations page


 

Search

More Analyst Conference Pages:

 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 EPZM
 GILD
 GLYC
 INCY
 INO
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

 
   
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2020 William P. Meyers